American Society for Microbiology, Antimicrobial Agents and Chemotherapy, 9(66), 2022
DOI: 10.1128/aac.00527-22
Full text: Unavailable
Metallo-β-lactamase (MBL)-producing Gram-negative bacteria cause infections associated with high rates of morbidity and mortality. Currently, a leading regimen to treat infections caused by MBL-producing bacteria is aztreonam combined with ceftazidime-avibactam.